Mid-Atlantic

cures-within-reach-rare-diseasesWhile Cures Within Reach is disease-agnostic and geography-agnostic, some of our funding partners have strategic interests in specific geographic regions.  Therefore, in addition to our disease-specific repurposing communities, we work to increase the repurposing research focused on improving the quality and length of life within the Mid-Atlantic region through the speed and cost-effectiveness of medical repurposing.

Our events and research within the the Mid-Atlantic Repurposing Community all focus on connecting our many stakeholder groups together in our shared goal: driving more treatments to more patients more quickly through repurposing.

Events

 

Repurposing for Pediatric Patients: Best Practices and Lessons Learned
November 2020
Virtual
A patient-focused conversation on the opportunities that repurposing drugs, devices and other treatments provide for the pediatric patient population.

How Patients Impact the 505(b)(2) Regulatory Process
October 2020
Virtual
A patient-focused conversation on the 505(b)(2) regulatory process and how patients, caregivers and patient advocacy groups can engage with both industry and regulators to support the drug development process, share their real-world perspectives for clinical trial planning and represent the patient view throughout the drug approval process.

CureAccelerator Live for Chicago 2020
September 2020
Virtual
Five finalists from the US competing for up to $50,000 to fund their repurposing clinical trials.

CureAccelerator Live! for Rare Diseases 2020
June 2020
Virtual
Five finalists from the US competing for up to $50,000 to fund their repurposing clinical trials impacting rare disease patients.

CureAccelerator Live! for Rare Diseases 2019
June 2019
Philadelphia, PA
Three finalists from the US and Italy competing for up to $50,000 to fund their repurposing clinical trials impacting rare disease patients.

CureAccelerator Live! for the Mid-Atlantic 2018
October 2018
Washington, DC
Four finalists from Mid-Atlantic institutions competing for up to $50,000 to fund their groundbreaking repurposing clinical trials.